India is the pharmacy of the world — and is moving up the value chain into biologics, medical devices, digital health and specialised manufacturing. Global companies need a structured India programme that converts sector scale into the right partners, regulatory pathways and executable commercial plans.
In pharma specifically, R&D, manufacturing/quality, and commercial/sales each buy differently — a solution for clinical trials looks nothing like one for supply chain. If you don’t understand the core operations, you end up aligning the wrong technology with zero outcomes to validate. RevTract bridges this knowledge gap and helps design the right framework to the customer operations. Right technology with real and tangible outcomes build customers for life.
India supplies about 20% of global generic medicines by volume and ranks third worldwide by volume. With the highest number of USFDA-compliant plants outside the USA, opportunities span complex generics, differentiated formulations, CDMO partnerships and quality-led supply into regulated markets.
The sector is shifting from volume to value — complex generics, biosimilars and specialty medicines. Global innovators and biosimilar developers can partner on manufacturing scale, clinical programmes, regulatory pathways and commercial access across India and export markets.
India’s API market is a critical node in global supply, with strong domestic and export demand. PLI-backed capacity, process chemistry partnerships and dual-sourcing strategies create openings for technology providers, contract manufacturers and strategic investors.
Medical devices exports reached $4.1 Bn in FY25, with the market projected toward $50 Bn by 2030. PLI projects are enabling domestic manufacturing of MRI, CT, LINACs, stents and implants — opening routes for global MedTech firms in local production, technology transfer and hospital channel build-out.
Ayushman Bharat Digital Mission has scaled ABHA health accounts past 90 crore, while PM-JAY continues to expand cashless care through tens of thousands of empaneled hospitals. Opportunities span EHR interoperability, telemedicine, AI diagnostics, claims platforms and hospital operations technology.
India is a global leader in low-cost vaccine supply and a major destination for clinical research. Global sponsors, CROs and vaccine technology partners can leverage trial infrastructure, manufacturing scale and public-health programmes to accelerate development and access agendas.
Whether you're entering formulations, biologics, medical devices, digital health or clinical research, we can help you move faster with clarity.